Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.

Item

http://www.wikidata.org/entity/Q35626262

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Role of frontline autologous s ...... arge B-cell lymphoma patients.

@ast

Role of frontline autologous s ...... arge B-cell lymphoma patients.

@en

type

Item

label

Role of frontline autologous s ...... arge B-cell lymphoma patients.

@ast

Role of frontline autologous s ...... arge B-cell lymphoma patients.

@en

prefLabel

Role of frontline autologous s ...... arge B-cell lymphoma patients.

@ast

Role of frontline autologous s ...... arge B-cell lymphoma patients.

@en

P1476

Role of frontline autologous s ...... large B-cell lymphoma patients

@en

P2093

Chang-Ki Min

http://www.w3.org/2001/XMLSchema#string

Chong-Won Park

http://www.w3.org/2001/XMLSchema#string

Hee-Je Kim

http://www.w3.org/2001/XMLSchema#string

Jae-Ho Yoon

http://www.w3.org/2001/XMLSchema#string

Jong-Wook Kim

http://www.w3.org/2001/XMLSchema#string

Jong-Wook Lee

http://www.w3.org/2001/XMLSchema#string

Ki-Seong Eom

http://www.w3.org/2001/XMLSchema#string

Seok Lee

http://www.w3.org/2001/XMLSchema#string

Sung-Eun Lee

http://www.w3.org/2001/XMLSchema#string

Woo-Sung Min

http://www.w3.org/2001/XMLSchema#string

P2860

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis.

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.

High-dose chemotherapy in childhood brain tumors.

P304

362-371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3904/KJIM.2015.30.3.362

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Seok-Goo Cho

P577

2015-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276464241

http://www.w3.org/2001/XMLSchema#string

P698

25995667

http://www.w3.org/2001/XMLSchema#string

P932

4438291

http://www.w3.org/2001/XMLSchema#string